This analysis examines the current position and future outlook for Wyeth in the ethical pharmaceutical sector. It encompasses company strategy, comparative portfolio and pipeline analysis and assessment of financial performance, providing 1, 3 and 6 year sales forecasts for key drugs.Evaluate to what extent the negative publicity surrounding the safety of the Premarin family of hormone therapies will impact Wyeth's growth to 2007Assess Wyeth's dependence on sales of the anti-depressant Effexor, anticipated to record sales in excess of $3 billion by 2007Understand why Datamonitor belives Wyeth will be a key player in the next round of industry consoldiation following the Pfizer/Pharmacia mergerBenchmark Wyeth’s performance with key rivals in the ethical pharmaceutical sector
